CollPlant Biotechnologies (NASDAQ:CLGN) Given Hold Rating at D. Boral Capital

D. Boral Capital reaffirmed their hold rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a research report sent to investors on Friday, MarketBeat.com reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CollPlant Biotechnologies in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, CollPlant Biotechnologies has a consensus rating of “Hold” and an average price target of $11.50.

CollPlant Biotechnologies Stock Up 6.7%

CLGN stock opened at $0.80 on Friday. CollPlant Biotechnologies has a 52 week low of $0.66 and a 52 week high of $4.98. The stock has a market capitalization of $10.22 million, a PE ratio of -0.78 and a beta of 2.28. The firm has a 50 day moving average of $1.62 and a 200 day moving average of $2.15.

CollPlant Biotechnologies (NASDAQ:CLGN) last posted its quarterly earnings data on Wednesday, November 26th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of $0.38 by ($0.65). CollPlant Biotechnologies had a negative return on equity of 102.00% and a negative net margin of 491.31%.The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $16.52 million. On average, equities research analysts expect that CollPlant Biotechnologies will post -1.44 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. AMH Equity Ltd lifted its holdings in CollPlant Biotechnologies by 28.7% in the second quarter. AMH Equity Ltd now owns 160,849 shares of the company’s stock valued at $219,000 after acquiring an additional 35,849 shares during the period. Pinnacle Associates Ltd. lifted its stake in shares of CollPlant Biotechnologies by 3.7% in the 2nd quarter. Pinnacle Associates Ltd. now owns 507,193 shares of the company’s stock valued at $690,000 after purchasing an additional 18,000 shares during the period. Finally, Villere ST Denis J & Co. LLC lifted its stake in shares of CollPlant Biotechnologies by 13.0% in the 2nd quarter. Villere ST Denis J & Co. LLC now owns 546,867 shares of the company’s stock valued at $744,000 after purchasing an additional 63,000 shares during the period. 21.69% of the stock is currently owned by hedge funds and other institutional investors.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.